NCT05976607

Brief Summary

The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Renal Tumor. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 20, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 26, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 4, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2024

Completed
Last Updated

April 17, 2025

Status Verified

April 1, 2025

Enrollment Period

7 months

First QC Date

July 26, 2023

Last Update Submit

April 14, 2025

Conditions

Renal Tumor

Outcome Measures

Primary Outcomes (1)

  • Correlation between clinical indicators and PET/CT results

    Correlation of Clinical immunohistochemical indexes, ultrasound, enhanced CT, MRI, laboratory examination indexes and 18F-FAPI-RGD PET/CT results

    2 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with diagnosed or highly suspected Renal Tumor

You may qualify if:

  • Age 18 and above
  • No gender difference
  • Patients who have been diagnosed with, or are clinically highly suspected of, renal tumors and have had no other treatment within 3 months

You may not qualify if:

  • Patients with a second primary tumor
  • Pregnant or breastfeeding
  • Severe liver or kidney disease
  • Claustrophobia or other PET/CT scan contraindications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Departments of Nephrology, Sichuan Provincial People's Hospital

Chengdu, Sichuan, 610072, China

Location

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 26, 2023

First Posted

August 4, 2023

Study Start

June 20, 2023

Primary Completion

January 15, 2024

Study Completion

February 20, 2024

Last Updated

April 17, 2025

Record last verified: 2025-04

Locations

CN(1)